Anti-CD44 x Anti-CR3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD44 and anti-CR3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can recruit macrophages to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY